Key points are not available for this paper at this time.
An increasing number of reports indicate that endogenously produced inhibitors of nitric oxide synthase, particularly asymmetric dimethylarginine (ADMA), regulate nitric oxide generation in disease states. This article describes the biology of ADMA and the implications for cardiovascular physiology and pathophysiology.
Vallance et al. (2004) studied this question. Asymmetric dimethylarginine (ADMA) functions as an endogenous inhibitor of nitric oxide synthase, regulating nitric oxide generation in cardiovascular disease states.